Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, S. K. | - |
dc.contributor.author | Chung, H. J. | - |
dc.contributor.author | Chung, M. W. | - |
dc.contributor.author | Kim, J. -I. | - |
dc.contributor.author | Kang, J. -H. | - |
dc.contributor.author | Woo, S. W. | - |
dc.contributor.author | Bang, S. | - |
dc.contributor.author | Lee, S. H. | - |
dc.contributor.author | Lee, H. J. | - |
dc.contributor.author | Roh, J. | - |
dc.date.accessioned | 2021-09-09T03:55:30Z | - |
dc.date.available | 2021-09-09T03:55:30Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2008-10 | - |
dc.identifier.issn | 0269-4727 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/122625 | - |
dc.description.abstract | Background and objective: Genetic polymorphism of CYP2D6 leads to differences in pharmacokinetics of CYP2D6 substrates. The CYP2D6*10 allele is clinically important in Koreans because of its high frequency in Asians. We investigated whether the pharmacokinetics of metoprolol was altered by the presence of the CYP2D6*10 allele in Korean subjects. Methods: One hundred and seven volunteers were recruited and grouped as CYP2D6*1/*1, CYP2D6*1/*10 and CYP2D6*10/*10 according to their genotypes. Metoprolol tartrate 100 mg (Betaloc((R))) was administered orally once to each subject in these three groups (n = 6, 7 and 5, respectively). The pharmacokinetic parameters of metoprolol and its metabolite, alpha-hydroxymetoprolol, and the metabolic ratio for the three groups were estimated and compared. Results and discussion: The area under the plasma concentration-time curve (AUC(0 ->infinity)), the maximum plasma concentration (C-max) and the elimination half-life (T-1/2) of metoprolol and alpha-hydroxymetoprolol for the CYP2D6*10/*10 group were all significantly different from those of the CYP2D6*1/*1 group (P < 0.05). The AUC(0 ->infinity)s of metoprolol were 443.7 +/- 168.1, 995.6 +/- 321.4 and 2545.3 +/- 632.0 ng.h/mL, and the AUC(0 ->infinity)s of alpha-hydroxymetoprolol were 1232.0 +/- 311.2, 1344.0 +/- 288.1 and 877.4 +/- 103.4 ng.h/mL for groups CYP2D6*1/*1, *1/*10 and *10/*10, respectively. The corresponding T-1/2 values of metoprolol were 2.7 +/- 0.5, 3.2 +/- 1.3 and 5.0 +/- 1.1 h, while those of alpha-hydroxymetoprolol were 5.4 +/- 1.5, 6.0 +/- 1.4 and 10.5 +/- 4.2 h, respectively. The metabolic ratios of the three groups were significantly different (P < 0.05). Conclusion: The CYP2D6*10 allele altered the pharmacokinetics of metoprolol in Korean subjects and is likely to affect other drugs metabolized by the CYP2D6 enzyme, similarly. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | PERFORMANCE LIQUID-CHROMATOGRAPHY | - |
dc.subject | CYTOCHROME-P450 2D6 | - |
dc.subject | OXIDATION POLYMORPHISM | - |
dc.subject | CHINESE SUBJECTS | - |
dc.subject | CYP2D6 | - |
dc.subject | METABOLISM | - |
dc.subject | DEBRISOQUINE | - |
dc.subject | RELEVANCE | - |
dc.subject | GENOTYPE | - |
dc.subject | GENETICS | - |
dc.title | Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, S. H. | - |
dc.identifier.doi | 10.1111/j.1365-2710.2008.00945.x | - |
dc.identifier.scopusid | 2-s2.0-52049120158 | - |
dc.identifier.wosid | 000259310000015 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.33, no.5, pp.567 - 573 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.title | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.volume | 33 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 567 | - |
dc.citation.endPage | 573 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | GENOTYPE | - |
dc.subject.keywordPlus | GENETICS | - |
dc.subject.keywordPlus | PERFORMANCE LIQUID-CHROMATOGRAPHY | - |
dc.subject.keywordPlus | CYTOCHROME-P450 2D6 | - |
dc.subject.keywordPlus | OXIDATION POLYMORPHISM | - |
dc.subject.keywordPlus | CHINESE SUBJECTS | - |
dc.subject.keywordPlus | CYP2D6 | - |
dc.subject.keywordPlus | METABOLISM | - |
dc.subject.keywordPlus | DEBRISOQUINE | - |
dc.subject.keywordPlus | RELEVANCE | - |
dc.subject.keywordAuthor | CYP2D6 | - |
dc.subject.keywordAuthor | Korean | - |
dc.subject.keywordAuthor | Metoprolol | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.